In this context, imaging CD8-positive T-cells can help clinicians predict which glioblastomas are likely to respond to CD8-focused immunotherapeutics, while simultaneously ensuring that T-cell infiltration is robust enough to warrant treatments like immune checkpoint inhibitors. Here, CD8A is linked to glioblastoma.